Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

Pfizer PFE-1.80%decrease; red down pointing triangle punched back against activist investor Starboard Value on Tuesday, delivering positive quarterly results. The pharmaceutical company raised its ...

Wall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based pharma giant delivered better-than-expected financials for Q3 2024 and ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - The Pfizer logo is displayed at the company’s headquarters, Friday, Feb. 5, 2021, in New York. (AP ...

Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession.

Pfizer (PFE) CEO Albert Bourla is bullish about the company's near-term outlook after a flubbed attack campaign from activist investor Starboard Value earlier this month. "We have launched an ...

At Least $4 Billion Anticipated by End of 2024 from Cost Realignment Program (5) Approximately $1.5 Billion Expected by End of 2027 from First Phase of Manufacturing Optimization Program NEW ...

Despite that underperformance over the past 2 months, I believe Pfizer stock still deserves its "Buy" rating. In my opinion, the company is likely to exceed the third-quarter 2024 consensus ...

Pfizer PFE will report its third-quarter 2024 earnings on Oct. 29, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.19 billion and 64 cents per share ...

Yet, despite three options on the market from Pfizer, GSK and Moderna, uptake has been slow so far this season. In a note to clients earlier this month, Jefferies analyst Michael Yee noted how ...